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The earliest blood vessels in the mammalian embryo are formed when endothelial cells 
(ECs) differentiate from angioblasts and coalesce into tubular networks. Thereafter, the 
endothelium is thought to expand solely by proliferation of pre-existing ECs. Here we show 
that the earliest precursors of erythrocytes, megakaryocytes and macrophages, the yolk 
sac-derived erythro-myeloid progenitors (EMPs), provide a complementary source of ECs 
that are recruited into pre-existing vasculature. Whereas a first wave of yolk sac-resident 
EMPs contributes ECs to the yolk sac endothelium, a second wave of EMPs colonises the 
embryo and contributes ECs to intraembryonic endothelium in multiple organs, where they 
persist into adulthood. By demonstrating that EMPs constitute a hitherto unrecognised 
source of ECs, we reveal that embryonic blood vascular endothelium expands in a dual 
mechanism that involves both the proliferation of pre-existing ECs and the incorporation of 
ECs derived from hematopoietic precursors.  
Blood vessels distribute oxygen, nutrients, hormones and immune cells through the vertebrate 
body and help remove waste molecules. Accordingly, functional blood vessel formation during 
embryogenesis is a prerequisite for vertebrate life. Endothelial cells (ECs) form the inner lining of 
blood vessels; they first arise from mesenchymal precursors termed angioblasts on embryonic day 
(E) 7.0 in mice 1. After condensing into yolk sac vasculature and the paired dorsal aortae, ECs 
proliferate within existing endothelium to increase vascular diameter, sprout into avascular tissue 
areas or remodel into smaller vessels by intussusceptive growth 1. Current consensus is therefore 
that embryonic ECs are a self-contained cell lineage that expands without contribution from new 
angioblasts or circulating precursors. In contrast, circulating endothelial progenitors have been 
proposed to exist in the adult, although their relationship to myeloid cells (MCs) remains 
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controversial 2. 
In addition to their primary roles in the innate immune system, MCs such as monocytes and 
macrophages also modulate vascular growth 3. For example, the tissue-resident macrophages of 
the embryonic mouse brain, termed microglia, contact ECs at the tip of neighbouring vessel 
sprouts to promote their anastomosis into perfused vessel loops 4. In contrast, a direct contribution 
of MCs to embryonic vascular endothelium has not been reported; thus, genetic lineage tracing 
with the myeloid Vav or Lyz2 (Lysm) promoters does not mark embryonic blood vascular 
endothelium in mice 5, 6.  
Most tissue-resident macrophages arise from erythro-myeloid progenitors (EMPs) that form in the 
extra-embryonic yolk sac during embryogenesis and also serve as precursors for erythrocytes and 
megakaryocytes 7-11. In mice, an early EMP wave, also referred to as primitive hematopoietic 
progenitors, buds from yolk sac endothelium between E7.0 and E8.25 and differentiates by E9.0 
into yolk sac macrophages without monocytic intermediates 7, 10, 12-14. These macrophages colonise 
the embryo proper to generate tissue-resident macrophages, such as microglia in the brain or 
Langerhans cells in the epidermis 13. A later EMP wave buds from yolk sac endothelium from 
E8.25 onwards and colonises the liver after the embryonic circulation is established 7, 8, 11, 14, 15. 
These later-born EMPs expand in the liver into monocytes that subsequently differentiate into 
tissue-resident macrophages in many organs but not the brain 7, 13.  
 
Lineage tracing with Csf1r-iCre identifies ECs in developing brain vasculature 
To target early EMPs 7, 10, 12, microglia 16, 17 and other differentiated MCs 18, we and others have 
used a transgene that expresses CRE recombinase under the promoter for the myeloid lineage 
gene Csf1r (Fms), which encodes the colony-stimulating factor 1 receptor, CSF1R. Microglia 
appear as single YFP+ cells in hindbrains from Csf1r-iCre mouse embryos carrying the RosaYfp 
recombination reporter, with microglia and ECs also stained for isolectin B4 (IB4) (Fig. 1a) 16. As 
previously shown 4, the number of IB4+ YFP+ microglia peaked in the hindbrain subventricular zone 
at E11.5, when vessels fuse into the subventricular vascular plexus (SVP) (Fig. 1b). Surprisingly, 
we also observed sporadic, elongated IB4+ YFP+ cells that appeared bound into the endothelium 
and increased steadily during SVP expansion (Fig. 1a-c; Extended Data Fig. 1a). Csf1r-iCre-
targeting of vessel-bound cells was not an artefact caused by spontaneous RosaYfp recombination 
or unspecific immunostaining, because littermates lacking Csf1r-iCre lacked YFP staining (Fig. 1a). 
Furthermore, imaging of Csf1r-iCre hindbrains carrying CAG-Cat-Egfp or RosatdTom as alternative 
recombination reporters confirmed targeting of both microglia and vessel-bound elongated cells 
(Extended Data Fig. 1b,c). The tamoxifen-induced activation of CRE expressed from an 
independently generated Csf1r-Mer-iCre-Mer transgene that also targets MCs 19 similarly targeted 
vessel-bound cells in addition to microglia (Fig. 1d). Corroborating the endothelial identify of Csf1r-
iCre-targeted vessel-bound cells, they expressed the EC markers ERG and PECAM1, had a 
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similar morphology to ECs targeted with the endothelial-specific Cdh5-CreERT2 transgene, formed 
junctions with neighbouring ECs via the endothelial cadherin CDH5 and lacked both myeloid and 
pericyte markers (Fig. 1e, Extended Data Fig. 1d-f).  
Csf1r-iCre-mediated EC targeting was not explained by Csf1r expression of brain ECs, because 
hindbrain ECs, unlike microglia, lacked expression of a Csf1r-Egfp transgene that faithfully reports 
Csf1r promoter activity 20, 21 and accordingly did not contain CSF1R protein (Extended Data Fig. 
2a,b). Moreover, the analysis of published transcriptomic datasets 22 showed that Csf1r is not 
expressed in ECs from embryonic brain, liver or lung, and RT-qPCR analysis of tdTom+ ECs 
isolated by fluorescence-activated cell sorting (FACS) confirmed that they expressed Cdh5, but not 
Csf1r or the myeloid gene Spi1, which encodes the PU.1 transcription factor (Extended Data Fig. 
2c-g). The lack of endothelial Csf1r expression suggests that Csf1r-iCre-targeted brain ECs arise 
from precursors that activate Csf1r prior to their incorporation into hindbrain vasculature. These 
precursors cannot be differentiated MCs such as microglia, whose formation is PU.1-dependent 4, 
because PU.1 deficiency did not reduce the number of Csf1r-iCre-targeted ECs in the E11.5 
hindbrain (Fig. 1f-h) or postnatal day (P) 0 striatum (Extended Data Fig. 2h). We therefore 
investigated whether Csf1r-iCre-targeted ECs are derived from PU.1-independent, Csf1r-
expressing precursors.  
 
Csf1r-iCre-targeted ECs and EMPs share PU.1-independent spatiotemporal origins 
As EMPs are PU.1-independent 23, we investigated whether the formation of Csf1r-iCre-targeted 
ECs is spatiotemporally linked to the emergence of Csf1r-expressing EMPs from yolk sac 
hemogenic endothelium, which was visualised by staining for the EC marker VEGFR2. E8.5 Csf1r-
Egfp yolk sacs contained clusters of round EGFP+ VEGFR2+ cells that protruded from endothelium 
into the vascular lumen (Fig. 2a), consistent with prior work showing that FACS-isolated EMPs 
express both Csf1r 7 and Vegfr2 9, and that EMPs bud from yolk sac endothelium 11. Csf1r-iCre 
lineage tracing in E8.5 yolk sacs similarly identified YFP+ round cells that protruded into the 
vascular lumen, were VEGFR2+, persisted in PU.1-deficient yolk sacs and expressed the EMP 
marker KIT 7 (Fig. 2b,c; Extended Data Fig. 3a,b). Even though EGFP expression could not be 
detected in Csf1r-Egfp yolk sac endothelium (Fig. 2a), Csf1r-iCre;RosaYfp also targeted a subset of 
flat yolk sac ECs (Fig. 2b), which lacked obvious KIT expression (Extended Data Fig. 3b), 
excluding that they were hemogenic ECs 24. Similar to Csf1r-iCre-targeted hindbrain ECs, the 
lineage-traced yolk sac ECs were PU.1-independent (Fig. 2b,c).  
The finding that EMP formation correlates with the emergence of Csf1r-iCre-targeted yolk sac ECs 
was corroborated by temporally restricted Csf1r-Mer-iCre-Mer-mediated lineage tracing. As 
tamoxifen-induced, CRE-mediated reporter recombination peaks approximately 6 h and ends 24 h 
after tamoxifen injection 25, we activated Csf1r-Mer-iCre-Mer;RosatdTom in discrete temporal 
windows by single injections at E8.5, E9.5 or E10.5 before identifying lineage-traced cells in E12.5 
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yolk sacs (Extended Data Fig. 3c). Inductions at all three stages labelled yolk sac macrophages 
(Extended Data Fig. 3d), consistent with their origin from Csf1r-expressing EMPs 7 and their 
maintenance of Csf1r expression 10, 12. Additionally, E8.5 or E9.5 induction yielded tdTom+ ECs, 
whereas E10.5 induction did not (Extended Data Fig. 3d). As EMPs are present in the yolk sac at 
E8.5 and E9.5, but home to the liver thereafter 13, their local availability makes them plausible 
precursors of Csf1r-iCre-labelled yolk sac ECs. In agreement, tamoxifen induction of a KitCreERT2 
knockin allele at E8.5, when KIT+ early EMPs are still present in the yolk sac 7, lineage-traced both 
yolk sac ECs and macrophages (Extended Data Fig. 3e,f).  
In contrast to early wave EMPs that remain in the yolk sac, the late wave EMPs that populate the 
embryo are reported to lack Csf1r expression, at least when they form in the yolk sac 7. We 
therefore investigated whether late wave EMPs begin to express Csf1r after liver homing and if 
they are the precursors of the Csf1r-targeted ECs that appear in the hindbrain from E10.5 
onwards. Thus, we combined the Csf1r-Egfp expression reporter with Csf1r-Mer-iCre-
Mer;RosatdTom and induced CRE-mediated recombination at E10.5; 24 h later, we FACS-separated 
the differentiated MCs from EMPs and EMP-derived myeloid progenitors (MPs) 7 in the liver and 
blood (Fig. 3a,b). The differentiated MC populations from both sources contained tdTom+ EGFP+ 
cells, as expected, but notably, tdTom+ EGFP+ cells were also present in both the liver and blood 
EMP/MP populations (Fig. 3a,b; Extended Data Fig. 3g-i). These findings suggest that a subset 
of intraembryonic EMPs expresses Csf1r and can access organs such as the hindbrain via the 
circulation. 
To determine whether the intraembryonic presence of Csf1r-expressing late wave EMPs correlated 
with the emergence of Csf1r-iCre-targeted hindbrain ECs, we visualised tdTom expression in 
E12.5 Csf1r-Mer-iCre-Mer;RosatdTom hindbrains after E8.5, E9.5 and E10.5 tamoxifen induction 
(Fig. 3c). The hindbrain vasculature contained tdTom+ ECs following induction at E10.5, but not 
E8.5 or E9.5, even though the Csf1r-expressing microglia were targeted at all stages (Fig. 3d). 
KitCreERT2 induction at E8.5 also caused microglia targeting (Fig. 3e,f), agreeing with microglia 
arising from yolk sac macrophages generated around E8.5 from KIT+ early wave EMPs 7. KitCreERT2 
induction at E8.5, when late wave EMPs begin to arise in the yolk sac 7, also yielded tdTom+ ECs 
in the E12.5 hindbrain (Fig. 3e,f), corroborating that yolk sac-born EMPs can give rise to 
intraembryonic ECs. Lineage tracing from three independent Cre alleles therefore suggests that 
EMPs give rise to both yolk sac and hindbrain ECs.  
 
The Csf1r-iCre-targeted EMP lineage gives rise to ECs in vitro 
The myeloid and erythroid potential of EMPs has been demonstrated through in vitro differentiation 
11, 26. Using similar assays, we compared the endothelial potential of FACS-isolated differentiated 
MC and EMP/MP populations from E12.5 Csf1r-iCre;RosatdTom liver and blood (Fig. 4a,b). Both cell 
populations were mostly tdTom+ (Fig. 4c,d). As expected 7, the EMP-containing population was 
   
- 5 - 
comprised of round cells with a large nucleus and little cytoplasm, whereas the MC population 
contained granulocytes, in addition to monocytes in the liver and macrophages in the blood (Fig. 
4c,d) For culture, we used methocult to promote the formation of hematopoietic colonies, but 
included a fibronectin (FN) substrate to facilitate EC differentiation. Differentiated MCs persisted in 
these cultures as single round/amoeboid cells (Fig. 4e,f) that were tdTom+ ERGlo VEGFR2lo (Fig. 
4g,h; antibody controls in Extended Data Fig. 4a,b). In contrast, both liver and blood EMPs 
formed myeloid and erythroid cell colonies in suspension (Fig. 4e,f) and additionally gave rise to 
single adherent cells that appeared spindle-shaped, were tdTom+ ERGhi VEGFR2hi and lacked 
myeloid cell markers, consistent with an EC identity (Fig. 4g,h; Extended Data Fig. 4c). Together, 
these experiments demonstrate that EMPs have endothelial potential alongside their known 
hematopoietic capacity. 
 
Csf1r-iCre-targeted ECs support the growth of embryonic brain vasculature 
Hoxa cluster genes modulate haematopoiesis 27 and are upregulated in postnatal compared to 
adult ECs 28, with HOXA9 also promoting EC differentiation from progenitors in adult ischemic 
disease 29. Our analysis of published transcriptomic data 9, 30 revealed that Hoxa transcripts are 
enriched in E10.25 compared to E9.0 EMPs or macrophages (Fig. 5a). To investigate whether 
Hoxa-deficiency impairs the formation of EMP-derived hindbrain ECs, we combined Csf1r-iCre 
with a conditional null Hoxa cluster mutation (Hoxafl) (Extended Data Fig. 5a). Gene copy analysis 
showed effective gene targeting in KIT+ cells from E12.5 Csf1r-iCre;Hoxafl/fl mutant compared to 
control livers, but the number of CD45+ cells, including differentiated MCs, was not reduced 
(Extended data Fig. 5b-f). Hoxa genes are therefore dispensable for MC specification from late 
wave EMPs. In contrast, significantly fewer tdTom+ ECs, also derived from late wave EMPs, had 
formed in RosatdTom-carrying Csf1r-iCre;Hoxafl/fl mutant compared to control hindbrains; moreover, 
SVP complexity was significantly reduced in mutant hindbrains (Fig. 5b-d). Although we observed 
20% fewer microglia in mutant compared to control hindbrains (Extended data Fig. 5g-i), this 
unlikely contributed to the vascular defect, because even a 50% microglia reduction in Csf1op/+ 
mutants did not reduce SVP complexity (Extended data Fig. 5j-l). Together, these findings 
suggest that Hoxa cluster genes promote the formation of EMP-derived brain ECs, which in turn 
support normal brain vascular development.  
 
EMP-derived ECs have a core endothelial transcriptional signature and preferentially 
contribute to liver vasculature  
Csf1r-iCre-targeted ECs not only appeared morphologically similar to neighbouring ECs (Fig. 1), 
but also had similarly slow proliferation and overall cell cycle kinetics (Extended Data Fig. 6). 
Moreover, RNA-Seq analysis of FACS-isolated tdTom+ and tdTom- ECs from E12.5 Csf1r-
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iCre;RosatdTom embryos showed that they had largely similar transcriptomes, with only few 
differentially expressed genes, including the expected difference in the tdTomato transcript (Fig. 
6a-c; Extended Data Fig. 7a). Corroborating their endothelial identity, tdTom+ ECs lacked markers 
for differentiated MCs and other non-EC lineages, but expressed core EC transcripts at similar 
levels to tdTom- ECs (Fig. 6d,e). Amongst the differentially expressed genes, markers typical of 
EC specialisation were under-represented in tdTom+ ECs, such as ephrins and EPH receptors 
regulating arteriovenous differentiation (Fig. 6e). This observation agrees with Csf1r-iCre-targeted 
ECs being derived from progenitors that are recruited into preformed vascular endothelium. 
Whereas brain EC markers (e.g. Slc2a1) were under-represented in the embryo-wide tdTom+ EC 
population, liver EC markers were over-represented (e.g. Oit3, Mrc1), including early markers of 
liver sinusoidal differentiation (Stab2, Lyve1) 31 (Fig. 6c,f; Extended data Fig. 7b,c). Similar 
expression of Oit3 and Mrc1 in tdTom+ and tdTom- liver ECs (Extended Data Fig. 7d) suggests 
that the over-representation of liver EC transcripts in the total embryonic tdTom+ EC population 
reflects their preferential contribution to liver vasculature. Immunostaining and FACS of Csf1r-
iCre;RosatdTom E12.5 and E18.5 embryos confirmed that tdTom+ ECs were more prevalent in liver 
endothelium than tdTom- ECs (Fig. 6g,i; Extended Data Figs. 8 and 9a,b). As liver EC 
specialisation markers were present in both tdTom- and tdTom+ liver ECs at E12.5 (Fig. 6g; 
Extended Data Fig. 8a), liver ECs of two distinct origins appear to undergo similar organ-specific 
EC differentiation. 
 
Csf1r-iCre-targeted ECs populate multiple embryonic organs and persist into adulthood  
Immunostaining and FACS analyses at E12.5 and E18.5 showed that Csf1r-iCre-targeted ECs 
were also present in heart and lung vasculature at similar levels to the brain (Fig. 6i; Extended 
Data Figs. 8 and 9a,b). Corresponding immunostaining and FACS analyses showed that tdTom+ 
ECs persisted in the brain, heart, lung and liver of adults and continued to dominate the adult liver 
sinusoidal endothelium (Fig. 6h,j; Extended Data Figs. 9c and 10a). Accordingly, all adult organs 
examined contained EMP-derived ECs.   
 
Discussion  
The heterogeneous origin of blood vascular mural cells from distinct populations of mesodermal 
progenitors, hematopoietic and neural crest cells is established 32. Here, we show that embryonic 
vascular endothelium is also heterogeneous in origin. Thus, ECs emerge via a classical pathway of 
angioblast differentiation into ECs and the pathway described in this report, which entails EC 
differentiation from the EMP lineage (Extended Data Fig. 10b). Multiple prior investigations have 
utilised Csf1r-iCre together with recombination reporters to follow the embryonic myeloid lineage 7, 
10, 12. These studies predominantly employed FACS using hematopoietic markers, which precluded 
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observation of Csf1r-iCre-targeted ECs. In contrast, we included EC markers in FACS protocols to 
additionally isolate Csf1r-iCre-targeted ECs. Immunostaining was previously also used to identify 
Csf1r-iCre-targeted cells in the retina 17, liver and colon 18, but without description of EC targeting, 
possibly because of the close spatial proximity of ECs and perivascular macrophages 4, 33. We 
have overcome this limitation by performing high resolution imaging of tissues immunostained with 
both EC and MC markers. The contribution of EMP-derived ECs to yolk sac, brain, heart and lung 
vasculature is proportionally smaller than that of ECs of classical origin, whereas EMP-derived 
ECs predominate the liver, particularly the sinusoidal endothelium. Liver endothelium was 
previously reported to be heterogeneous in origin, with an endoderm lineage contribution of 
approximately 15% and the remainder of the liver EC population attributed to a venous origin 34. 
Our results suggest that liver endothelium contains approximately 60% EMP-derived ECs. 
Preferential EMP homing to the liver after their entry into the embryonic circulation 13 and the 
dependence of liver growth on rapid vascular expansion 35 may explain the relatively large 
contribution of EMP-derived ECs to this organ. Ultimately, the discovery that EMPs provide a 
source of ECs for organ vasculature may open up new therapeutic avenues for vessel-dependent 
organ repair and regeneration. For example, EMPs or EMP-like EC progenitors, derived from 
human stem cells by modulating the expression of factors such as Hoxa genes, may be delivered 
systemically to support vascular growth in ischemic diseases or provide angiocrine signals that 
stimulate tissue stem cells. 
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Figure legends 
 
Fig. 1: Csf1r-iCre lineage tracing identifies ECs in developing brain vasculature. 
(a-c) Csf1r-iCre;RosaYfp hindbrains of the indicated gestational stages. (a) Wholemount labelling for 
YFP and IB4; (b) YFP+ IB4+ single cells (microglia) and YFP+ IB4+ vessel-bound cells (putative 
ECs) per 0.72 mm2, mean ± SD; (c) positive correlation between YFP+ putative EC number and 
vessel area (r2, coefficient of determination; goodness of fit, P < 0.01); each data point represents 
one hindbrain; n = 3 hindbrains for each group.  
(d,e) E12.5 hindbrains of the indicated genotypes, wholemount labelled with the indicated markers 
and shown including tdTom fluorescence; Csf1r-Mer-iCre-Mer;RosatdTom (d) was tamoxifen-
induced on E10.5 and Cdh5-CreERT2;RosatdTom (e) on E11.5; n = 3 hindbrains for each genotype.   
(f-h) Csf1r-iCre;RosaYfp E11.5 hindbrains on a Pu.1+/+ versus Pu.1-/- background, labelled for YFP 
and F4/80 together with IB4. The boxed area in (f) was 3D surface rendered and is shown in (g) en 
face and as a lateral view starting at the plane indicated by the yellow line; the vascular lumen (lu) 
is outlined. (h) YFP+ microglia (Pu.1+/+ n = 4 and Pu.1-/- n = 3 hindbrains) and ECs (Pu.1+/+ n = 6 
and Pu.1-/- n = 7 hindbrains); mean ± SD; each data point represents one hindbrain; n.s., non-
significant; ***P < 0.0001 (two-tailed unpaired t-test).  
Symbols: Microglia and ECs are indicated with arrowheads and arrows, respectively; solid and 
clear symbols indicate the presence or absence of marker expression, respectively.  
Scale bars: 20 µm (a,d,f), 50 µm (e). 
 
Fig. 2: Csf1r-iCre-targeted ECs emerge concomitantly with EMPs in the yolk sac. 
E8.5 yolk sacs were wholemount labelled with the indicated markers. (a) Csf1r-Egfp yolk sacs. 
(b,c) Csf1r-iCre;RosaYfp yolk sacs on a Pu.1+/+ versus (b) Pu.1-/- background (c). N = 4 yolk sacs 
for each genotype. The yellow lines mark the start of 3D-rendered lateral views. Wavy arrows 
indicate VEGFR2+ EGFP+ or VEGFR2+ YFP+ round cells corresponding to EMPs protruding from 
the vascular wall into the lumen (lu); straight arrows indicate YFP+ VEGFR2+ flat cells 
corresponding to ECs within the vascular wall. Scale bars: 20 µm. 
 
Fig. 3: Csf1r-iCre-targeted hindbrain ECs emerge from intraembryonic EMPs.  
(a,b) A pregnant Csf1r-Egfp;Csf1r-Mer-iCre-Mer;RosatdTom dam was injected with a single 
tamoxifen dose on E10.5 (a) before FACS of E11.5 liver and blood cells (b) to gate the CD45hi KIT- 
differentiated MCs (blue) and CD45lo KIT+ EMP/MP populations (pink) for EGFP and tdTom (n = 4 
embryos).  
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(c-f) Pregnant Csf1r-Mer-iCre-Mer;RosatdTom (c,d) and KitCreERT2;RosatdTom (e,f) dams were injected 
with a single tamoxifen dose on the indicated days before E12.5 hindbrain wholemount staining for 
the indicated markers and imaging including tdTom fluorescence; n = 3 independent experiments 
for each condition. Symbols: Arrows indicate tdTom+ ECs, arrowheads macrophages/microglia and 
the wavy arrow a cluster of tdTom+ ERG- IB4- neural cells derived from Kit+ neural progenitors. 
Scale bars: 20 µm. 
 
Fig. 4: EMPs in the liver and blood give rise to ECs in vitro.  
(a,b) FACS strategy to separate the differentiated MC and EMP/MP populations from E12.5 Csf1r-
iCre;RosatdTom liver (a) and blood (b) using antibodies for CD45 and KIT after excluding PECAM1+ 
cells to prevent EC contamination.  
(c,d) tdTom+ proportion in the FACS-isolated MC and EMP/MP populations from liver and blood 
shown in (a,b), and Giemsa-Wright staining of representative cells (Mo, monocyte; GC, 
granulocyte; Mφ, macrophage).  
(e-h) Brightfield images of myeloid (white) and erythroid (rust-coloured) colonies (e,f) and 
immunofluorescence of adherent cells (g,h) after three days in methocult (met.) on FN. Adherent 
cells were immunolabelled for ERG and VEGFR2, counterstained with DAPI and are shown 
together with tdTom fluorescence (Tom). Symbols: Arrows indicate tdTom+ ECs, arrowheads 
tdTom+ MCs; solid and clear symbols indicate high versus low marker expression, respectively. 
Scale bars: 20 µm. 
(a-h) N=3 independent experiments. 
 
Fig. 5: Csf1r-iCre-targeted ECs form in a Hoxa-dependent mechanism and promote 
vascularisation in the embryonic hindbrain. 
(a) Transcriptomic analysis of the indicated cell populations for the indicated genes, based on 
published RNA-Seq and EC microarray data 9, 30, shows that Hoxa transcripts are enriched in 
intraembryonic EMPs; white and black represent low versus high relative expression; Mφs, 
macrophages; YS, yolk sac; HUVECs, human umbilical cord ECs; Adgre1 and Ptprc, encode 
F4/80 and CD45, respectively; RNA-Seq n = 2 for each group, except for E10.25 YS (n = 4) and 
head Mφs (n = 3); microarray n = 3 for each group. 
(b-d) E12.5 littermate hindbrains of the indicated genotypes. (b) Wholemount labelling for the 
indicated markers; RFP staining to visualise tdTom. Symbols: arrows and arrowheads indicate 
tdTom+ ECs and microglia, respectively. Scale bars: 50 µm. (c) tdTom+ EC relative to IB4+ EC 
volume in Hoxa+/+ (n = 3) versus Hoxafl/fl (n = 7) hindbrains on a Csf1r-iCre;RosatdTom background; 
mean ± SD. (d) SVP complexity, measured as fold change of vascular branchpoints in 
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Hoxafl/fl;Csf1r-iCre (n = 9) relative to control hindbrains (pooled Csf1r-iCre+;Hoxa+/+ and Csf1r-iCre- 
hindbrains of any Hoxa genotype, n = 13). Mean ± SD; each data point represents one hindbrain; 
*P = 0.0184 (c), *P = 0.0323 (d) (two-tailed unpaired t-test). 
 
Fig. 6: The Csf1r-iCre-targeted EC population has a core endothelial transcription signature 
with an increase in liver EC transcripts and persists in adult organs.  
(a-f) Transcriptomic analysis. (a) FACS strategy to isolate tdTom- and tdTom+ ECs from E12.5 
Csf1r-iCre;RosatdTom embryos for RNA-Seq. (b) Graphic representation of genes whose expression 
is significantly different (green dots) and similar (black dots) between both EC populations. (c) 
Volcano plot of significantly differentially expressed transcripts with > 100 counts per transcript; 
selected genes are named; grey and red data points represent transcripts in tdTom- ECs with ≥ 2-
fold over- or under-representation, respectively. Relative expression levels for: (d) markers typical 
of myeloid (Cx3cr1-Ptprc), astrocytic (Gfap), smooth muscle (Acta2), neuronal (Rbfox3, Nefl), 
skeletal muscle (Myog) or epithelial (Cdh1) differentiation; (e) EC core and maturation markers; (f) 
representative brain and liver EC specialisation markers, shown alongside their relative expression 
in brain versus liver/lung ECs microarrays 30. Mean ± SD; RNA-Seq, n = 3 embryos (DESeq2; 
Benjamini-Hochberg’s multiple comparisons test for p-value adjustment, adjP); microarray, n = 5 
organs for both groups (2-way ANOVA, Bonferroni’s multiple comparisons test); ns, non-
significant, *P < 0.05, **P < 0.01, ***P < 0.0001; see Source Data Figure 6 for exact values. 
(g,h) Csf1r-iCre;RosatdTom E12.5 (g) and adult (h) liver cryosections, labelled for the indicated 
markers and RFP to visualise tdTom, including DAPI counterstaining in (h); n = 3 livers per age. 
Symbols: Arrows and arrowheads indicate tdTom+ ECs and macrophages, respectively; clear 
arrowheads indicate that macrophages lack VEGFR2.  Scale bar: 50 µm. 
(i,j)  FACS of Csf1r-iCre;RosatdTom E12.5 (i) and adult (j) brain, heart, lung and liver to determine 
their relative tdTom+ EC content; mean ± SD; n = 5 organs each (i; except lung, n = 4), n = 6 
organs each (j; except liver, n = 7); each data point represents one organ; ***P < 0.0001 (i); **P = 
0.0023, 0.0066, 0.00541 (j) for liver versus brain, heart, lung, respectively (1-way ANOVA, Tukey’s 
multiple comparisons test). 
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(online only) Methods plus associated references 
 
Mouse strains. All animal procedures were performed in accordance with the institutional Animal 
Welfare Ethical Review Body (AWERB) and UK Home Office guidelines. To obtain mouse 
embryos of defined gestational age, mice were paired in the evening and the presence of a vaginal 
plug the following morning was defined as E0.5. In some studies, we analysed adult mice, defined 
as more than 8 weeks of age (12 weeks for Fig. 6h and 24 weeks for ED Fig. 10a).  Mice carrying 
the Csf1r-iCre transgene 18 were mated to the mice with Cre recombination reporters, either 
RosaYfp 36, RosatdTom 37 or CAG-cat-Egfp 38. PU.1+/- mice 39 were mated to RosaYfp mice and then 
Csf1r-iCre mice to obtain Csf1r-iCre;RosaYfp;Pu.1-/- embryos that lack differentiated MCs including 
microglia 4, 39, 40 as well as the MC precursors of skin pericytes 41. Hoxafl/fl mice 42 were mated to 
RosatdTom mice and then Csf1r-iCre to obtain Csf1r-iCre;RosatdTom;Hoxafl/fl embryos. Csf1r-Mer-
iCre-Mer 19 and KitCreERT2 43 as well as endothelial-specific Cdh5-CreERT2 41, 44 mice were mated to 
RosatdTom mice. In some experiments, mice carrying the Csf1r-Egfp-Ngfr/Fkbp1a/Tnfrsf6 (short: 
Csf1r-Egfp) reporter of Csf1r expression 21 were mated to Csf1r-Mer-iCre-Mer;RosatdTom mice. We 
also used mice with a heterozygous loss of function mutation in Csf1 (Csf1Op) 45. All mouse strains 
were maintained on a mixed background (C57Bl6/J;129/Sv), with the exception of Csf1r-Mer-iCre-
Mer, which was maintained on a mixed FVB:C57/Bl6/J background. For tamoxifen induction of 
CRE activity, tamoxifen (Sigma) was dissolved in peanut oil and administered via a single 
intraperitoneal injection into each pregnant dam. For Csf1r-Mer-iCre-Mer induction, we injected 1 
mg tamoxifen; to achieve mosaic Cdh5-Cre-ERT2 activation, we injected 20 µg tamoxifen; for KitCre-
ERT2 induction at E8.5, we injected 3 mg tamoxifen together with 1.75 mg progesterone to increase 
induction without inducing abortions (Sigma).  
Immunolabelling. Samples were fixed in 4% formaldehyde in PBS and processed as 
wholemounts or dehydrated in sucrose and embedded in optimal cutting temperature (OCT, 
Tissue-Tek) compound to cut 20 µm cryosections. Immunolabelling was performed as described 
previously for wholemount hindbrains 46. We used the following antibodies and dilutions: goat anti-
CDH5 (1:200; AF1002, lot FQI0116101, R&D Systems), rabbit anti-CSF1R (1:500; sc-692, lot 
K1212, Santa Cruz), rat anti-EMCN (1:50; sc-65495, lot C2917, Santa Cruz), rabbit anti-ERG 
(1:200; ab92513, lot GR32027 69-1, Abcam), rat anti-F4/80 (1:500; MCA497R, lot 1605, Serotec), 
chicken anti-GFP (1:1000; GFP-1020, lot 0511FP12, Aves) and rabbit anti-GFP (1:500; 598, lot 
079, MBL) for YFP or EGFP labelling, rabbit anti-IBA1 (1:500; 019-19741, Wako Chemicals), rat 
anti-KIT (1:500; 553353, lot 30259, BD Pharmingen), rabbit anti-NG2 (1:200; AB5320, lot 2726769, 
Millipore), rat anti-PECAM1 (1:200; 553370, lot 5205656, BD Pharmingen), rabbit anti-pHH3 
(1:400; 06-570, lot 2825969, Millipore), rabbit anti-RFP (1:1000; PM005, lot 045, MBL), goat anti-
VEGFR2 (1:200; AF644, lot COA0417021, R&D Systems). Secondary antibodies used included 
Alexa Fluor-conjugated goat anti-chick, -rabbit or -rat IgG (Life Technologies), or, for primary 
antibodies raised in goat, donkey fluorophore-conjugated FAB fragments of anti-chick, -goat, -
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rabbit or -rat IgG (Jackson ImmunoResearch). Note that CDH5 47, ERG 48, EMCN 49, PECAM1 50 
and VEGFR2 51 were used as EC markers, whereas F4/80 52 and IBA1 53 were used as 
macrophage markers and NG2 54 as a pericyte marker. Biotinylated IB4 (L2140, lot 085M4032V, 
Sigma) followed by Alexa-conjugated streptavidin (ThermoFisher) was also used to detect brain 
ECs and microglia 4, 16. Nuclei were labelled with DAPI. Images were acquired with a LSM710 laser 
scanning confocal microscope (Zeiss) and processed using LSM image browser (Zeiss) and 
Photoshop CS4 (Adobe) software. Three-dimensional rendering including surface rendering and 
the generation of virtual slices for lateral views of high-resolution confocal z-stacks was performed 
using Imaris (Bitplane). Z-stack projections of confocal images are shown unless indicated 
otherwise in the figure legends. 
Fluorescence-activated cells sorting (FACS) and cell culture. Tissues were mechanically and 
enzymatically homogenised in RPMI1640 with 2.5% foetal bovine serum (ThermoFisher), 100 
µg/ml collagenase/dispase (Roche), 50 µg/ml DNAse (Qiagen) and 100 µg/ml heparin (Sigma), 
incubated for 5 mins with 0.5 mg/ml rat Fc block (Becton Dickinson) and labelled with a 
combination of PE/Cy7-conjugated rat anti-PECAM1 (clone 390, cat 102418, lot B212262), FITC-
conjugated rat anti-CD45 (clone 30-F11, cat 103108, lot B246762) or CD41 (clone MWReg30, cat 
133903, lot B201955), APC-conjugated rat anti-KIT (clone 2B8, cat 105812, lot B217855) and 
PerCp/Cy5.5-conjugated rat anti-CD11b (clone M1/70, cat 101227) (all Biolegend). Appropriate 
fluorescence gating parameters were established with unstained tissue, Csf1r-iCre- or Csf1r-Egfp-
negative tissues and fluorescence-minus-one (FMO) staining. For cell cycle analysis, cell 
populations were incubated with 10 µg/ml Hoechst 33342 (Sigma) for 30 mins at 37˚C 55 before 
labelling with PE/Cy7-conjugated rat anti-PECAM1 and performing FACS analysis. In all 
experiments, doublets were eliminated using pulse geometry gates (FSC-H versus FSC-A and 
SSC-H versus SSC-A), whereas dead cells were removed using SYTOX Blue (Life Technologies) 
or LIVE/DEAD Fixable Violet (Life Technologies). Single cell suspensions were analysed using the 
BD LSRFortessa X-20 cell analyser or sorted using the BD Influx cell sorter (BD Biosciences); 
FlowJo software (FlowJo LLC) was used for subsequent analyses. In some experiments, a fraction 
of each population was cytospun onto a glass slide for Wright-Giemsa staining (Sigma) followed by 
imaging using an LSM510 microscope equipped with an AxioCam MRc camera (Zeiss). For cell 
culture experiments, cell populations were sorted into DMEM with 100 U/ml penicillin, 100 U/ml 
streptomycin and 20% foetal bovine serum (all ThermoFisher) before seeding the cells into a 96-
well plate coated with 10 µg/ml fibronectin (ThermoFisher) to facilitate EC differentiation. Cells 
were then cultured in methocult (Stemcell Technologies) to promote the formation of hematopoietic 
colonies, which were imaged using a TS100 microscope equipped with a DS-5M colour camera 
(Nikon). After removal of methocult, adherent cells were fixed with 4% formaldehyde in PBS and 
then labelled for VEGFR2, ERG, CD45, F4/80 and CSF1R (see above) before imaging using a Ti-
E microscope (Nikon).  
RNA-Seq. PECAM1+ CD45- CD11b- KIT- ECs were isolated from E12.5 Csf1r-Cre;RosatdTom 
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embryos and divided into tdTom+ and tdTom- populations with the BD Influx cell sorter before RNA 
was extracted with the RNeasy Micro Kit (QIAGEN). cDNA was generated and amplified using the 
SMART-seq V4 ultra low input RNA kit (Clontech). 100 pg of amplified cDNA per sample was used 
to prepare a library with the Nextera XT kit (Illumina) and run on the NextSeq 500 sequencer 
(lllumina). Raw sequence data were pre-processed to trim poor quality base calls and adapter 
contamination using Trimmomatic v.0.36.4 56 and aligned to the mouse mm10 genome with STAR 
v.2.5.2b 57. Mapped reads were deduplicated to reduce PCR bias using Picard v2.7.1.1 software 
(http://broadinstitute.github.io/picard/), and the reads-per-transcript were then calculated using 
FeatureCount v1.4.6.p5 software 58. Differential expression was performed using the BioConductor 
package DESeq2 via the SARTools wrapper v1.3.2.0 59. 
Reverse transcription polymerase chain reaction (PCR). We extracted RNA from FACS-
isolated cells with the BD Influx cell sorter (see above) with the RNeasy Micro Kit for cDNA 
synthesis with Superscript IV (ThermoFisher). The genotypes and ages of the analysed samples 
are indicated in the relevant figure legends. Quantitative (q) RT-PCR was performed with SYBR 
Green on an HT7900 system (Applied Biosystems) using the following oligonucleotide pairs: Actb  
5’-CACCACACCTTCTACAATGAG-3’ and 5’-GTCTCAAACATGATCTGGGTC-3’;  
Cdh5 5’-GATGCAGATGACCCCACTGT-3’ and 5’-AGGGCATCTTGTGTTCCAC-3’;  
Csf1r 5’-TGCGTCTACACAGTTCAGAG-3’ and 5’-ATGCTGTATATGTTCTTCGGT-3’;  
Spi1 5’-GCCATAGCGATCACTACTG-3’ and 5’-CAAGGTTTGATAAGGGAAGC-3’;  
Hoxa11 5’-TCTTTGCCTCTCTCCTTCCTT-3’ and 5’-TTGCAGACGCTTCTCTTTGTT-3’;  
Evx1 5’-GTGTGCTCTGGGCTCCTGT-3’ and 5’-GCCAGGGTGCCTTGAGAG-3;  
Slc2a1 5’-CCCCAGAAGGTTATTGAGGAGT and 5’-ACAAAGAGGCCGACAGAGAA;  
Mrc1 5’-ACTGGGCAATGCAAATGGAG and 5’- CCCTCAAAGTGCAATGGACA;  
Oit3 5’-CGTCTGCTTCCATGTCTACTG and 5’-GTGCTCACATTCATTTTCGTCA. For each 
oligonucleotide pair, a no-template control reaction was included.  
 
Microarray analysis. Published microarray data were used to compare gene expression levels 
(normalized log2OD) in E14.5 CD45- PECAM1+ brain versus pooled lung and liver ECs  
(GSE35802)  22 and  in  cultures  of HUVECs versus  adult  retinal  ECs  (GSE20986) 30 using 
GEO2R software (NCBI). 
Statistical Analysis. Tissues for analysis were allocated to experimental groups according to 
genotype and gestational age. The number of YFP+ ECs and YFP+ microglia in Csf1r-iCre;RosaYfp 
hindbrains (Fig. 1a,b and 1f-h) was determined in three randomly chosen 0.72 mm2 regions of 
each wholemount labelled and flatmounted hindbrain. For hindbrains in Hoxa-targeting 
experiments, the number of F4/80+ microglia (Extended Data Fig. 5) and tdTom+ and IB4+ volume 
(Fig. 5b,c) were determined from confocal z-stacks of four randomly chosen 0.18 mm2 regions on 
the lateral side of each hindbrain (Extended Data Fig. 5g). The z-stacks were surface rendered 
with Imaris (Bitplane) to obtain the F4/80+, tdTom+ and IB4+ volumes, and the F4/80+ volume was 
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then subtracted from both the IB4+ and tdTom+ total volume to obtain the IB4+ EC and tdTom+ EC 
volume before calculating the ratio of tdTom+ to IB4+ EC volume. To determine the number of 
vascular branchpoints in Hoxa-targeting experiments (Fig. 5b,d), the same confocal z-stacks were 
analysed with Imaris filament tracer after F4/80+ microglia were masked. For Fig. 1 and Fig. 5, all 
counts obtained from one hindbrain were averaged to yield the value for that hindbrain; to ensure 
unbiased interpretation of results, the genotypes were disclosed only after data collection was 
complete. For all experiments, we calculated the mean value for at least 3 independent samples, 
where error bars represent the standard deviation of the mean (for details, see figure legends). 
Comparison of medians against means justified the use of a parametric test; to determine whether 
two datasets were significantly different, we therefore calculated p values with a two-tailed 
unpaired Student’s t test; P < 0.05 was considered significant. When more than two data sets were 
compared, we used the statistical tests indicated in the associated figure legends. Statistical 
analyses were performed with Excel 12.2.6 (Microsoft Office) or Prism 5 (GraphPad Software).  
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Extended data figure legends: 
 
Extended data figure 1: Endothelial Csf1r-iCre targeting is observed with different 
recombination reporters and targeted ECs are distinguishable from macrophages and 
pericytes.  
(a-c) Csf1r-iCre;RosaYfp (a) Csf1r-iCre;CAG-Cat-Egfp (b) and Csf1r-iCre;RosatdTom (c) hindbrains 
at the indicated stages were wholemount labelled with IB4 and for YFP (a) or GFP (b) or are 
shown together with tdTom fluorescence (c); n = 3 hindbrains for each genotype. In (a), the white 
squares indicate areas which were imaged at higher magnification for Fig. 1a. The indicated single 
channels are also shown individually in grey scale.  
(d) Csf1r-iCre;RosatdTom E12.5 hindbrains, wholemount labelled for ERG and CDH5 and shown 
including tdTom fluorescence to demonstrate that Csf1r-iCre targets ECs that form junctions with 
neighbouring, non-targeted ECs; n = 3 hindbrains.  
(e,f) E12.5 Csf1r-iCre;RosaYfp hindbrains, labelled for YFP and the microglia marker F4/80 (e) or 
the pericyte marker NG2 (f) together with IB4, show that Csf1r-iCre-targeted vessel-bound cells 
are neither microglia nor pericytes; n = 3 hindbrains each. In (e), the boxed area is shown in higher 
magnification and as single channels adjacent to the panel. In (f), a single optical y/z cross section 
at the position indicated with the yellow line is displayed at higher magnification with single 
channels.  
Symbols: Microglia and ECs are indicated with arrowheads and arrows, respectively, pericytes with 
double arrowheads, junctional CDH5 staining with a curved arrow; solid and clear symbols indicate 
the presence or absence of marker expression, respectively.  
Scale bars: 100 µm (a), 20 µm (b,c,e,f), 50 µm (d). 
 
Extended data figure 2: Endothelial Csf1r-iCre-targeting is not caused by endothelial Csf1r 
expression and occurs independently of myeloid differentiation. 
(a,b) Csf1r-Egfp (a) and Csf1r-iCre;RosaYfp (b) E11.5 hindbrains, wholemount labelled for CSF1R 
and EGFP or YFP together with IB4, show lack of Csf1r promoter activity and CSF1R protein in 
ECs; n = 3 hindbrains for each genotype.  
(c) Graphic representation of relative Cdh5 and Csf1r expression levels in E14.5 brain or pooled 
lung/liver EC microarrays 22; n = 5 organs for each group; data are shown as mean ± SD; each 
data point represents the value for one organ; ***P < 0.0001 (two-tailed unpaired t-test).  
(d-g) FACS separation of tdTom+ cells from Csf1r-iCre;RosatdTom embryos for gene expression 
analysis, including (d) representative gating strategy to exclude dead cells and doublets in this and 
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subsequent experiments and (e) sorting into PECAM1+ CD45- ECs versus CD45+ PECAM1- MCs. 
(f) Representative RT-qPCR gene amplification graphs for Csf1r versus Actb from tdTom+ MCs 
and ECs; ΔRn, normalised reporter value for SYBR Green minus baseline instrument signals. (g) 
Graphic representation of the fold change in RT-qPCR amplification of the indicated genes relative 
to Actb for both cell populations; n = 3 embryos; data are shown as mean ± SD; each data point 
represents the value of one embryo; *P = 0.0242, ***P < 0.0001 (two-tailed unpaired t-test). 
(h) Csf1r-iCre;RosaYfp P0 striatum on a Pu.1+/+ versus Pu.1-/- background, cryosectioned and 
labelled for YFP and F4/80 together with IB4 to show that Csf1r-iCre-targeted ECs are PU.1-
independent and persist postnatally; n = 3 brains each.  
Symbols: Arrowheads indicate microglia, arrows YFP+ ECs, clear arrows YFP+ ECs that are 
CSF1R- and F4/80-.   
Scale bars: 20 µm. 
 
Extended data figure 3: Lineage tracing of yolk sac and liver EMPs.  
(a,b) E8.5 wild type (a) and Pu.1-/- (b) yolk sacs on a Csf1r-iCre;RosaYfp background, wholemount 
labelled for YFP and KIT, contain Csf1r-iCre-targeted KIT+ round cells corresponding to EMPs and 
Csf1r-iCre-targeted KIT- flat cells corresponding to ECs; n = 3 yolk sacs for each genotype Scale 
bars: 20 µm. 
(c-f) Pregnant Csf1r-Mer-iCre-Mer;RosatdTom (c,d) and KitCreERT2;RosatdTom (e,f) dams were injected 
with a single tamoxifen dose on the indicated days and E12.5 yolk sacs were wholemount labelled 
for VEGFR2, ERG or EMCN to identify Csf1r-iCre-targeted ECs; yolk sacs are shown including 
with tdTom fluorescence, which identifies macrophages and a subset of ECs; n = 3 yolk sacs for 
each genotype. Symbols: Wavy arrows indicate EMPs, straight arrows Csf1r-iCre-lineage-traced 
ECs, arrowheads macrophages; solid and clear symbols indicate the presence or absence, 
respectively, of the indicated markers. Scale bars: 20 µm.  
(g-i) Pregnant dams were injected with a single tamoxifen dose on E10.5 (g) before FACS analysis 
of E11.5 Csf1r-Egfp;Csf1r-Mer-iCre-Mer;RosatdTom (h) or Csf1r-Mer-iCre-Mer;RosatdTom control (i) 
livers for the indicated markers; the CD45hi KIT- differentiated MCs (blue), CD45lo KIT+  EMP/MP 
populations (pink) and the CD45- KIT+ populations (grey) were gated further for Csf1r-Egfp and 
tdTom; CD45- KIT+ cells were neither MCs nor EMPs, because they lacked CD45, tdTom and 
EGFP; n = 4 livers in (g-i). 
 
Extended data figure 4: Immunostaining controls for cultured Csf1r-iCre-targeted cells.  
The indicated cell populations were FACS-isolated from E12.5 Csf1r-iCre;RosatdTom liver or blood 
with the indicated markers and cultured for three days in methocult (met.) on fibronectin (FN). 
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Adherent cells from tdTom+ liver MC (a) and EMP/MP (b) cultures were stained for ERG and 
VEGFR2 (top panels) or with secondary antibodies only (bottom panels). In (c), adherent cells 
from tdTom+ blood EMP/MP cultures were immunostained for CSF1R together with the myeloid 
markers CD45 (top panels) or F4/80 (bottom panels). In the first panel in each row, the phase 
contrast and DAPI images were merged. In panels 2-4 in each row, immunolabelled cells were 
visualised together with tdTom fluorescence, with single channels for the indicated markers shown 
separately in grey scale; n = 1 experiment. Symbols: Arrows indicate tdTom+ ECs, arrowheads 
tdTom+ myeloid cells; solid and clear symbols indicate the presence or absence, respectively, of 
the indicated markers. Scale bars: 20 µm. 
 
Extended data figure 5: Hoxa gene targeting with Csf1r-iCre.  
(a) Schematic representation of the Hoxa gene cluster and adjacent Evx1 gene using the UCSC 
Genome Browser with the mouse December 2011 (GRCm38/mm10) Assembly, including position 
of the LoxP sites used for gene targeting.  
(b-c) Validation of Hoxa targeting. (b) FACS strategy to isolate KIT+ cells from E12.5 control 
(pooled Csf1r-iCre- or Csf1r-iCre+;Hoxa+/+; n = 14), Hoxa+/fl;Csf1r-iCre (n = 6) and Hoxafl/fl;Csf1r-
iCre (n = 8) livers. (c) qPCR analysis of the KIT+ cells isolated in (b) for Hoxa gene copy number 
relative to Evx1; data are shown as mean ± SD; each symbol represents the value for one liver; * 
P=0.0156, *** P<0.001 (1-way ANOVA, Tukey’s multiple comparisons test).  
(d-f) Representative FACS analysis (d) and quantification (e,f) of liver cell populations at E12.5 
shows a similar number of total CD45+ and CD45+ CD11b+ differentiated MCs in Hoxafl/fl;Csf1r-iCre 
mutants (n = 7 for CD45+; n = 6 for CD45+ CD11b+) versus pooled Csf1r-iCre- and Csf1r-
iCre+;Hoxa+/+controls (n = 25 for CD45+, n = 17 for CD45+ CD11b+); data are shown as mean ± SD 
fold change in mutants compared to controls; each data point represents one liver; ns, non-
significant, P = 0.6519 (e) and P = 0.496 (f), (two-tailed unpaired t-test).   
(g-i) E12.5 hindbrains of the indicated genotypes were immunolabelled to determine vascular 
complexity and quantify microglia. (g) Schematic representation of a flatmounted embryonic 
hindbrain and location of the hindbrain areas i-iv that were viewed and imaged for quantification in 
(h,i); values for the four areas in each hindbrain were averaged to obtain the value for that 
hindbrain; EC quantifications are shown in Fig. 5c,d. (h) Hindbrains were wholemount labelled 
with IB4 and for RFP to visualise tdTom+ ECs and for F4/80 to visualise tdTom+ microglia; white 
boxes indicate areas shown in higher magnification in Fig. 5. (i) Quantification of microglia number 
in Hoxafl/fl;Csf1r-iCre mutants (n = 9) versus controls (n = 10, pooled Csf1r-iCre+;Hoxa+/+ and Csf1r-
iCre- of any Hoxa genotype); data are shown as the mean ± SD of the fold change in mutant 
compared to control hindbrain; each data point represents one hindbrain; **P = 0.0055 (two-tailed 
unpaired t-test).   
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(j-l) E11.5 Csf1+/+ and Csf1+/op littermate hindbrains, wholemount labelled for F4/80 together with 
IB4 (j) before quantification of microglia number (k) and vascular branchpoint number as a 
measure of vascular complexity (i). Data are shown as mean ± SD; n = 3 hindbrains for each 
genotype; each data point represents the value for one hindbrain; ns, non-significant, P = 0.808, 
**P = 0.0012 (two-tailed unpaired t-test).     
Scale bars: 200 µm (h), 100 µm (j). 
 
Extended data figure 6: Csf1r-iCre-targeted ECs proliferate in vivo. 
(a,b) E12.5 Csf1r-iCre;RosatdTom yolk sac (a) or hindbrain (b), wholemount stained for the 
proliferation marker pHH3 and VEGFR2 or for pHH3 together with IB4, respectively, and shown 
together with tdTom fluorescence (n = 3 for each organ). Areas indicated with white squares were 
imaged at higher magnification and are shown below the corresponding panel, with tdTom and 
pHH3 channels also shown separately in grey scale. Symbols: The arrows indicate proliferating 
tdTom+ pHH3+ ECs; solid and clear symbols indicate the presence or absence, respectively, of 
tdTom fluorescence; the wavy arrow indicates a tdTom- pHH3+ neural progenitor. Scale bars: 100 
µm (top panels), 20 µm (lower panels). 
(c-e) Cell cycle distribution of tdTom+ and tdTom- ECs. (c) FACS strategy to isolate tdTom+ 
PECAM1+ and tdTom- PECAM1+ ECs from E12.5 Csf1r-iCre;RosatdTom embryos. (d) Graphic 
representation of cell cycle distribution based on Hoechst 33342 fluorescence as a measure of 
DNA content; low and high staining intensity is observed in cells with a DNA ploidy of 2n (G0/G1 
phase) or 4n (G2/M phase), respectively; an intermediate staining intensity corresponds to S 
phase. (e) Quantification of the proportion of tdTom+ and tdTom- ECs in G1, S and G2/M based on 
the area of the corresponding peaks in (d); data are shown as mean ± SD; n.s., non-significant, P 
> 0.9999 (two-way ANOVA, Bonferroni’s multiple comparisons test). N = 3 embryos. 
 
Extended data figure 7: Validation of gene expression data from RNA-Seq and microarray 
studies.  
ECs were FACS-isolated from E12.5 Csf1r-iCre;RosatdTom embryos (n = 3) as in Fig. 6a to validate 
the RNA-Seq and microarray data shown in Fig. 6d-f. Slc2a1 was analysed as a representative 
brain EC-enriched transcript/differentiation marker, Mrc1 and Oit3 as representative liver EC-
enriched transcripts. 
(a) Relative transcript levels of the Gt(ROSA)26Sor (tdTomato) transcript by RNA-Seq of the E12.5 
tdTom+ and tdTom- EC populations, whose analysis is presented in Fig. 6a-f; mean ± SD of 
normalised counts, n = 3 embryos; **P = 0.0085 (two-sided unpaired t-test). 
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(b) RT-qPCR analysis for the indicated genes in tdTom+ versus tdTom- ECs isolated from whole 
E12.5 embryos (n = 5) to validate genes identified by RNA-Seq in Fig. 6e,f as differentially 
expressed. Data are shown as the mean ± SD of the fold change; ***P < 0.0001 (Slc2a1), ***P = 
0.0008 (Mrc1), **P = 0.0056 (Oit3) (two-sided unpaired t-test). 
(c) RT-qPCR analysis for the indicated genes in tdTom- ECs isolated from E12.5 brains versus 
livers to validate organ-specific transcript enrichment identified via microarray analysis shown in 
Fig. 6f.; n = 3 for each organ; data are shown as the mean ± SD of the fold change; *P = 0.019, 
**P = 0.0082, ***P < 0.0001 (two-sided unpaired t-test); ND, not detectable. 
(d) RT-qPCR analysis for the indicated genes to directly compare the expression levels of brain 
and liver EC differentiation markers in tdTom+ versus tdTom- ECs isolated from brains (n = 3) or 
livers (n= 5). Data are shown as the mean ± SD of the fold change; ns, non-significant, P = 0.9398 
(liver Slc2a1), P = 0.8045 (liver Mrc1), P = 0.6327 (liver Oit3), **P = 0.0073 (brain Slc2a1) (two-
sided unpaired t-test); ND, not detectable. 
 
Extended data figure 8: Csf1r-iCre-targeted ECs contribute to embryonic vasculature in 
multiple organs. 
(a) 20 µm cryosections of the indicated E12.5 Csf1r-iCre;RosatdTom organs (n = 3 each) were 
immunolabelled for the indicated EC markers together with antibodies for RFP to identify tdTom 
protein (top and bottom panels) or are shown with tdTom fluorescence (middle panels); single 
channels are shown in grey scale. The white boxes indicate the position of areas shown in higher 
magnification in Fig. 6g; note that some areas selected for higher magnification are not contained 
entirely within the field of view, and accordingly the boxes are shown incomplete. Scale bars: 200 
µm. 
(b) Gating strategy for FACS analysis of tdTom+ and tdTom- ECs from E12.5 Csf1r-iCre;RosatdTom 
brain, lung, heart and liver and control organs lacking iCre, using antibodies for CD11b, CD41, 
CD45, KIT, PECAM1; associated EC quantifications are shown in Fig. 6i. An analogous strategy 
was used for the quantifications shown in Fig. 6j and in the Extended Data Fig. 9b. 
 
Extended data figure 9: Csf1r-iCre-targeted ECs contribute to organ vasculature in late 
stage embryos and adults.  
(a) 20 µm cryosections of the indicated organs from E18.5 Csf1r-iCre;RosaYfp mice were 
immunolabelled for YFP, the EC marker PECAM1 and the macrophage marker IBA1; single 
channels are shown in grey scale; n = 2 organs each. Symbols: Arrowheads indicate YFP+ IBA1+ 
macrophages; solid and empty arrows indicate ECs that are YFP+ and lack IBA1 expression, 
respectively. Scale bars: 20 µm. 
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(b) Flow cytometry of dissociated ECs from the indicated organs of E18.5 Csf1r-iCre;RosatdTom 
embryos after staining with antibodies for CD11b, CD41, CD45, KIT, PECAM1, using the gating 
strategy shown in the Extended data Fig. 8b; mean ± SD, n = 5 organs each; ***P < 0.0001 (1-
way ANOVA, Tukey’s multiple comparisons test). 
(c) 20 µm cryosections of the indicated organs from 6 month old adult Csf1r-iCre;RosaYfp mice 
were immunolabelled for YFP, the EC marker PECAM1 and the macrophage marker F4/80; single 
channels are shown in grey scale; n = 3 organs each. Symbols: Arrowheads indicate YFP+ and 
F4/80+ macrophages; solid and empty arrows indicate ECs that are YFP+ and lack F4/80 
expression, respectively. Scale bars: 20 µm. 
  
Extended data figure 10: Csf1r-iCre-targeted ECs contribute to adult organ vasculature. 
(a) 20 µm cryosections of 3 month old adult Csf1r-iCre;RosatdTom livers (n = 3) were 
immunolabelled for RFP and the EC marker VEGFR2 and the macrophage marker F4/80 or the 
liver EC sinusoidal EC marker MRC1 and then counterstained with DAPI; single channels are 
shown in grey scale. The white box indicates an area shown in higher magnification in Fig. 6h. 
Scale bars: 100 µm. 
(b) Working model for the role of EMPs in generating extra-embryonic yolk sac and intra-
embryonic organ ECs alongside their known role in generating myeloid and 
erythrocyte/megakaryocyte lineage cells. It is not yet known whether EMP-derived and non-EMP-
derived ECs have different functions to regulate normal organ physiology or pathological vascular 
responses in the adult.  
 
 
 
 
 
 










